Abstract:Background: Serous cystic neoplasm (SCN), mucinous cystic neoplasm (MCN), and intraductal papillary mucinous neoplasm (IPMN) comprise a large proportion of pancreatic cystic neoplasms (PCNs). Patients with MCN and IPMN require surgery due to the potential of malignant transformation, whereas those with SCN require periodic surveillance. However, the differential diagnosis of patients with PCNs before treatment remains a great challenge for all surgeons. Therefore, the establishment of a reliable diagnostic tool is urgently required for the improvement of precision diagnostics.Methods: Between February 2015 and December 2020, 143 consecutive patients with PCNs who were confirmed by postoperative pathology were retrospectively included in the study cohort, then randomized into development and test cohorts at a ratio of 7:3. The predictors of preoperative clinical-radiologic parameters were evaluated by univariate and multivariable logistic regression analyses. A total of 1,218 radiomics features were computationally extracted from the enhanced computed tomography (CT) scans of the tumor region, and a radiomics signature was established by the random forest algorithm. In the development cohort, multi- and binary-class radiomics models integrating preoperative variables and radiomics features were constructed to distinguish between the 3 types of PCNs. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to evaluate the predictive efficiency of the model. An independent internal test cohort was applied to validate the classification models.Results: All preoperative prediction models were built by integrating the radiomics signature with 13 diagnosis-related radiomics features and 3 important clinical-radiologic parameters: age, sex, and tumor diameter. The multiclass prediction model presented an overall accuracy of 0.804 in the development cohort and 0.707 in the test cohort. The binary-class prediction models displayed higher overall accuracies of 0.853, 0.866, and 0.928 in the development dataset and 0.750, 0.839, and 0.889 in the test dataset. In the test cohort, the binary-class radiomics models showed better predictive performances {AUC =0.914 [95% confidence interval (CI): 0.786 to 1.000], 0.863 (95% CI: 0.714 to 0.941), and 0.926 (95% CI: 0.824 to 1.000)} than the multiclass radiomics model [AUC =0.850 (95% CI: 0.696 to 1.000)], with a large net benefit in the decision curve analysis (DCA). The radiomics-based nomogram provided the correct predicted probability for the diagnosis of PCNs.Conclusions: The proposed radiomics models with clinical-radiologic parameters and radiomics features help to predict the accurate diagnosis among PCNs to advance personalized medicine.

Validation of Sendai and Fukuoka Consensus Guidelines in Predicting Malignancy in Patients with Preoperatively Diagnosed Mucinous Pancreatic Cystic Neoplasms.

The Clinical Utility of CA125/MUC16 in Pancreatic Cancer: A Consensus of Diagnostic, Prognostic and Predictive Updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements

The Way We Are Using to Improve the Preoperative Identification of Pancreatic Cystic Neoplasms: 213 Cases in A Single Chinese Pancreatic Surgery Center.

The Value of Systemic Inflammatory Markers in Identifying Malignancy in Mucinous Pancreatic Cystic Neoplasms

Evaluation of Predictive Factors for Malignancy in Cystic Neoplasms of Pancreas

A Predictive Scoring System Based on Inflammatory and Tumor Markers for Gastric Cancer Patients Undergoing Curative Resection

Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms?

AB086. P058. Current Status of Pancreatic Cystic Neoplasm: Diagnosis and Treatment a Multi-Institution Retrospective Study in China

A novel distinguishing system for the diagnosis of malignant pancreatic cystic neoplasm.

Online calculator for predicting the risk of malignancy in patients with pancreatic cystic neoplasms: A multicenter, retrospective study

Recurrence and Survival Prediction Models for Receiving Preoperative Chemotherapy Pancreatic Ductal Adenocarcinoma Cancer: A Single-center Retrospective Research

Evaluation of AGA and Fukuoka Guidelines for EUS and surgical resection of incidental pancreatic cysts

Predictive Values of Preoperative Markers for Resectable Pancreatic Body and Tail Cancer Determined by MDCT to Detect Occult Metastases

Preoperative diagnosis of the malignancy for pancreatic cystic neoplasms

Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 for Prediction of Malignancy and Invasiveness in Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Meta-Analysis.

Evaluation of the 2015 AGA guidelines on pancreatic cystic neoplasms in a large surgically confirmed multicenter cohort

Preoperative differentiation of pancreatic cystic neoplasm subtypes on computed tomography radiomics

Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas

Carbohydrate Antigen 125 Supplements Carbohydrate Antigen 19-9 for the Prediction of Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas

Surgical Resection and Outcome of Pancreatic Cystic Neoplasms in China: Analysis of a 16-Year Experience from a Single High-Volume Academic Institution